Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.
about
Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in KoreaThe Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell TransplantationRecent advances in haploidentical hematopoietic stem cell transplantation using ex vivo T cell-depleted graft in children and adolescentsThrombotic microangiopathy associated with proteasome inhibitorsA new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injuryHematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatmentTransplant-associated thrombotic microangiopathy: opening Pandora's box.Specific Etiologies Associated With the Multiple Organ Dysfunction Syndrome in Children: Part 1.Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab.Evaluation and management of patients with thrombotic thrombocytopenic purpura.Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: the Swiss connection.Posttransplant thrombotic microangiopathy: sensitivity of proposed new diagnostic criteria.Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning.Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange.Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation.Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT.Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation.Transplantation-associated thrombotic microangiopathy after steroid pulse therapy for polyserositis related to graft-versus-host disease.Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus.Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy?Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxisTacrolimus-associated thrombotic microangiopathy in a lung transplant recipientRenal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy.Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathyTMA: beware of complementsEculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options.Outcomes of plasma exchange in patients with transplant-associated thrombotic microangiopathy based on time of presentation since transplant.Abnormal echocardiography 7 days after stem cell transplantation may be an early indicator of thrombotic microangiopathy.Fragmented Red Cell as a Possible Favorable Prognostic Marker of Hematopoietic Stem Cell Transplantation Associated Thrombotic Microangiopathy.Pretransplant-corrected QT dispersion as a predictor of pericardial effusion after pediatric hematopoietic stem cell transplantation.The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy.Histologic Features of Intestinal Thrombotic Microangiopathy in Pediatric and Young Adult Patients after Hematopoietic Stem Cell TransplantationTransplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy.Treatment of thrombotic microangiopathy after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin.Post-bone marrow transplant thrombotic microangiopathy.
P2860
Q26739894-E265A816-FBB6-4324-A744-BFAF126F2543Q26740251-E9271E64-16DD-4A21-A10D-021AC4D5B43AQ26750995-292D0E6D-27B9-4C46-B284-DBFB9CF0C888Q26785826-0F380D7B-B9CC-45F5-80A3-35B08A54DED8Q26992169-2CB2C399-C995-4C05-86A4-0422783F8C8BQ28069228-767170ED-CAA7-480C-9C26-9B1FB508DFF8Q30235311-411B3A1B-8301-40DD-83CF-557B123A1630Q30253063-0D5CC87E-D639-4435-95B0-E4D9BC871529Q33256286-CC74A376-65B8-447B-9B86-B8AF3A6C9F8FQ33372991-69C43262-AB8F-4663-8930-3A688A26DA50Q33375004-06F7C7E2-CB19-46DF-A848-175E3A57424BQ33375739-D1B3DBC8-7CC2-4BFA-80F4-84B845DC245CQ33378414-4876C361-18FA-4F66-A783-C1CE548DF672Q33384578-84E834F4-63FD-498D-AF91-27195FC13B3CQ33386036-FBDDB210-52EC-4E1C-A459-025BCA09D928Q33386308-9BFBA7A6-B6A2-43DD-A072-3D5B220C1066Q33388255-2C9EB983-825A-477E-A006-7B570D1467D3Q33391308-306AAB76-E41B-48F9-A112-6D543B503802Q33392710-23C6A970-85BB-4BF1-A543-5D1E81384964Q33393068-23875A0D-DC72-47EF-9814-9BD6241195A9Q33395253-C9CAEE2E-4702-423E-BFAE-3C96D646D8D3Q33402385-C9D1F35F-CB5F-4FEB-B0F7-191EBB84C906Q33403897-87CD16D4-ABF2-48AE-B12D-12C0A8E4D637Q33405793-BE22BE61-BF12-449F-9763-6830B0F512F3Q33407913-743AEFF4-3455-4BF1-B1FD-DA527AF0EF17Q33408788-208A4880-8DBA-4AA4-87AC-C42EFD736CDEQ33410467-BA75FBF2-E4B4-45CF-9291-C4E388E2CBE9Q33412325-FDA808D1-5560-42FF-A10A-F482E9C2FF89Q33413498-13AF3B7B-1704-4810-8428-926BD1512EFDQ33417613-05FFB825-E5BF-454F-BFBA-A4487E2931B3Q33417690-2C4B52B4-7B4C-4F0D-8114-9E827D2F33E6Q33418088-98587357-F837-4DD8-BD67-BD67A80A9A7FQ33418635-093DA151-E014-463C-AFD8-BC474A5B1C7FQ33420131-6F4A3908-B485-4492-B9C6-491A34218E81Q33424153-9EC32CB7-7870-4694-892D-95F862112286Q33424204-F08562F9-577D-4AE3-8486-D5BAB9243F6AQ33424311-A6F333F4-3FCC-46CD-A10A-0761095734BDQ33424902-F5F4B438-20AD-42E0-9F4F-3DFCAA456C3FQ33428744-0C0625D0-5DF7-482D-9A2D-A11A0E4F24DFQ33430697-22A123F5-D947-48DF-80EF-3465957FBF7E
P2860
Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Blood and marrow transplant cl ...... tic stem cell transplantation.
@ast
Blood and marrow transplant cl ...... tic stem cell transplantation.
@en
type
label
Blood and marrow transplant cl ...... tic stem cell transplantation.
@ast
Blood and marrow transplant cl ...... tic stem cell transplantation.
@en
prefLabel
Blood and marrow transplant cl ...... tic stem cell transplantation.
@ast
Blood and marrow transplant cl ...... tic stem cell transplantation.
@en
P2093
P1476
Blood and marrow transplant cl ...... tic stem cell transplantation.
@en
P2093
Corey Cutler
James Ferrara
Mary Horowitz
Paul Martin
Robert Soiffer
Roberta Adams
Shelly Carter
Vincent T Ho
P304
P356
10.1016/J.BBMT.2005.06.001
P577
2005-08-01T00:00:00Z